Assessments and interventions for younger and female patients with RCC may need to be targeted, as these patients may have a greater fear of disease recurrence.
In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.
In a single-center study of 177 patients with metastatic renal cell carcinoma who received at least a single dose of an immune checkpoint inhibitor, the median time to next treatment was 8.9 months and median overall survival time was 26.7 months.
In a study, metastasectomy was associated with significantly longer median progression-free and overall survival in some mRCC patients.
Bone metastases less predictive in the setting of cytoreductive nephrectomy.